GLP-1 receptor agonists (GLP-1 RAs), medications that help control type 2 diabetes and obesity, can have a profound impact on physical wellness – but what about mental health?

Some examples of these medications include semaglutides, such as Ozempic and Wegovy, and liraglutide, like Victoza and Saxenda.

Various studies have pointed toward GLP-1 RAs causing mental health complications, such as anxiety and depression.

WEIGHT-LOSS DRUGS’ IMPACT ON CANCER RISK REVEALED IN NEW STUDY

The National Institutes of Health (NIH) published research in June 2024 that considered the correlation between semaglutide therapy and “exacerbating mood disturbances.”

The study highlighted the association of negative mood changes in patients with type 2 diabetes with a history of depression, warning healthcare providers to be aware of this “potential risk.”

But a more recent study, published in the journal Diabetes, Obesity and Metabolism, suggested that these mood changes were linked to genetic variations across diverse populations and ancestries within the U.K. Biobank. 

While GLP-1 RA variants had “consistent cardiometabolic effects” across all groups, the researchers said the negative impacts on mental health were “more varied,” concluding that any behavioral changes are “likely not acting directly through [the medications].”

SEMAGLUTIDE FOUND TO HAVE SHOCKING BENEFIT FOR LIVER DISEASE PATIENTS IN NEW STUDY

Doctors weigh in on medications and mood

Dr. Brett Osborn, a Florida neurosurgeon who often prescribes GLP-1 RAs to his patients, believes that there is “no consistent causal relationship” between these medications and mental illness.

“Researchers assayed genetic markers across almost half a million people from different backgrounds in search of a link between the gene behind GLP-1 receptors and mental health problems like depression, anxiety or suicidal ideation — and they didn’t find it,” he summarized.

GLP-1 receptor agonists have been linked to mood changes, patients and doctors have reported. (iStock)

People who are obese or battling type 2 diabetes are “often already depressed” without the medication, the doctor pointed out.

“These conditions take a toll – physically, emotionally and socially,” he said. “So, yes, a large portion of patients starting GLP-1 drugs are already dealing with mental health struggles. But that’s not because of the drug — that’s because of the disease.”

HERE’S WHY BELLY FAT IS MORE COMMON AS WE AGE, AND 3 WAYS TO PREVENT IT

Once these individuals begin dropping weight, blood sugar stabilizes and energy improves, which usually lifts their mood as well.

“GLP-1 drugs help people reclaim their health,” Osborn noted. “They reduce inflammation. They lower blood sugar. They shrink waistlines.” 

“And when people look and feel better, when their bodies finally start working for them instead of against them, they often smile more, not less.”

“GLP-1 drugs help people reclaim their health,” one doctor said. “And when people look and feel better, when their bodies finally start working for them instead of against them, they often smile more, not less.” (iStock)

Dr. Muhammad Ghanem, a bariatric surgeon at Orlando Health Weight Loss and Bariatric Surgery Institute, shared in a separate interview with Fox News Digital that while some of his patients have reported mood changes, others “don’t have that at all.”

FIRST GLP-1 PILL FOR WEIGHT LOSS, DIABETES SHOWS SUCCESS IN LATE-PHASE TRIAL

“Depression or mood changes are very common regardless, especially nowadays, and so it’s hard to [determine] whether this is related to the GLP-1 agonist medications, or whether it just happens to be that they started suffering from these after they started that medication,” he said.

“It’s really hard to tell whether it’s a personality change that can happen because of weight loss or if it’s a side effect because of mood changes,” he added. “I don’t think we have enough data to reach that conclusion yet.”

For those who are interested in GLP-1 RA medications or are experiencing mood changes while taking them, an expert stressed the importance of keeping in close contact with medical providers. (iStock)

Patients who lose weight with GLP-1 RAs can experience a “big boost” in confidence, as well as a change in personality and even relationships, according to Ghanem.

“It really depends on the person and the support system they have,” he said. “You need proper, randomized controlled trials to reach a conclusion, and better studies to determine whether this is related to the medication itself or just weight loss.”

“It’s important for all doctors who prescribe these drugs to be aware and check the patient’s history.”

Advertisement

For those who are interested in these medications or are experiencing mood changes while taking them, the surgeon stressed the importance of keeping in close contact with medical providers.

“Just like any other medication, they can have potential side effects,” he said.

Ghanem recommended seeking out professionals and practices who take a “holistic approach” to weight loss, offering mental health support in addition to medication.

Dr. Brunilda Nazario, MD, chief physician editor of medical affairs at WebMD, told Fox News Digital that “obesity is complicated.”

“Obesity specialists … are cautiously excited about how well these drugs work,” she said. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“With current studies showing conflicting results on mood disorders and the use of GLP-1 drugs, it’s important for all doctors who prescribe these drugs to be aware and check the patient’s history before prescribing [them].”

“Don’t be afraid to ask for help if you feel something is not right — your health depends on it,” one expert suggested. (iStock)

Nazario stressed that it’s “vital” for GLP-1 RA users to listen to their bodies, urging them to pay attention to their feelings and know the symptoms of mood disorders.

“Don’t be afraid to ask for help if you feel something is not right — your health depends on it,” he added.

For more Health articles, visit www.foxnews.com/health

Nazario noted that GLP-1 RAs can affect mood in many different ways.

“They are not all negative — they have the potential to improve mood as well,” she said. “Just seeing great results can boost self-esteem, confidence and body image.”

Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.

The first-ever blood test to detect Alzheimer’s disease has been cleared by the U.S. Food and Drug Administration (FDA).

In a Friday press release, the agency announced its approval of the first in-vitro diagnostic device, Lumipulse.

The method is intended for early Alzheimer’s detection in adult patients over the age of 55 who are exhibiting signs and symptoms of the disease.

ALZHEIMER’S DISEASE COULD BE PREVENTED ANTIVIRAL DRUG ALREADY ON MARKET

The new technology works by detecting amyloid plaques in the brain, a telltale sign of Alzheimer’s.

While PET scans can pick up these plaques, they can be “costly and time-consuming” while exposing patients to radiation, according to the FDA.

The new Lumipulse device reduces the need for a PET scan or other invasive testing, the agency said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

In a clinical study of 499 plasma samples from cognitively impaired adults, the Lumipulse test detected the presence of amyloid plaques in 91.7% of individuals.

The results indicate that the new blood test can “reliably predict the presence or absence of amyloid pathology associated with Alzheimer’s disease at the time of the test in patients who are cognitively impaired,” the FDA concluded.

The new technology works by detecting amyloid plaques in the brain, a telltale sign of Alzheimer’s, according to the FDA. (iStock)

The FDA noted the risk of false positive test results from Lumipulse, which could lead to inappropriate diagnosis and unnecessary treatment.

FDA Commissioner Marty Makary, M.D., MPH, wrote in a statement, “Alzheimer’s disease impacts too many people, more than breast cancer and prostate cancer combined.”

For more Health articles, visit www.foxnews.com/health

“Knowing that 10% of people aged 65 and older have Alzheimer’s, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients,” he said.

“Today’s clearance is an important step for Alzheimer’s disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease,” an expert commented. (iStock)

Center for Devices and Radiological Health Director Michelle Tarver, M.D., PhD, also commented in the press release that nearly seven million Americans are living with Alzheimer’s.

“And this number is projected to rise to nearly 13 million,” she said. 

“Today’s clearance is an important step for Alzheimer’s disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease.”